Over the past decade, wait times between a cancer diagnosis and first-course oncologic treatment have increased significantly across six major cancer types, according to a retrospective cohort study published in JAMA Surgery. Researchers utilizing the National Cancer Database examined 2,731,059 adult patient records diagnosed between 2012 and 2023 to evaluate systemic shifts in oncological care timelines.
In Plain English: The Clinical Takeaway
- First-Course Treatment: This refers to the initial medical intervention a patient receives after diagnosis, which can be either a definitive surgical removal or the start of neoadjuvant therapy (treatment given before primary surgery, such as chemotherapy or radiation).
- Retrospective Cohort Study: A medical research design that looks backward at existing patient databases to find patterns or links between past treatments and outcomes.
- Multidisciplinary Care: A team approach involving surgeons, medical oncologists, and radiation oncologists collaborating on a patient’s treatment plan, which can sometimes add steps before surgery occurs.
Decadal Trends Across Six Major Malignancies
The study evaluated adults with breast, colon, lung, pancreatic, gastric, or esophageal cancer who underwent potentially curative surgical resection. To account for contemporary changes in healthcare delivery—including health system consolidation, care centralization, and the COVID-19 pandemic—the researchers stratified the data across four distinct treatment periods: 2012–2015, 2016–2019, 2020–2021, and 2022–2023.
Across all evaluated cancer types, the median time from diagnosis to treatment increased significantly (P < .001 for trend). Many patients experienced prolonged wait times exceeding 30 days. According to findings highlighted by Cancer Therapy Advisor, median wait time increases included breast cancer shifting from 34 to 45 days, and colon cancer rising from 20 to 31 days. Lung cancer wait times increased from 41 to 53 days, pancreatic cancer moved from 23 to 32 days, gastric cancer from 35 to 49 days, and esophageal cancer from 38 to 48 days.
Hospital Type, Referrals, and Sociodemographic Disparities
The investigation revealed that academic and research hospitals consistently reported longer wait times than community hospitals or integrated network programs throughout the study period, although wait times grew across all facility categories. For instance, in the 2022–2023 timeframe, the median wait time for breast cancer treatment reached 49 days at academic hospitals, compared with 43 days at community hospitals and 45 days at integrated network centers.
Furthermore, patients who were diagnosed at one facility and subsequently referred to another experienced longer intervals before treatment commenced. Referred patients directed to high-volume hospitals faced the longest wait times across all six cancer types and all study periods. Sociodemographic factors also played a measurable role; being uninsured, possessing Medicaid insurance, traveling greater distances, and being Black were associated with increased wait times for five of the six cancer types.
The study authors noted that these upward trends appeared among patients undergoing both upfront surgery and neoadjuvant therapy. This indicates that the observed delays cannot be explained solely by the expanded use of multimodal neoadjuvant treatment paradigms.
Comparative Analysis of Treatment Delays by Facility Type (2022–2023)
| Cancer Type | Community Hospitals | Academic Hospitals | Integrated Network Programs |
|---|---|---|---|
| Breast Cancer | 43 days | 49 days | 45 days |
| Colon Cancer | 28 days | 35 days | 31 days |
| Lung Cancer | 53 days | 54 days | 51 days |
| Pancreatic Cancer | 32 days | 32 days | 31 days |
| Gastric Cancer | 46 days | 51 days | 47 days |
| Esophageal Cancer | 47 days | 50 days | 46 days |
Public Health Implications and the Push for Systemic Reform
As cancer care continues to centralize within expanding, consolidated health systems, the structural friction points causing these delays require urgent administrative attention. Public health agencies and clinical networks are increasingly tasked with improving care coordination, streamlining referral pathways, and standardizing timelines to ensure timely access to curative-intent surgical interventions.
